Lonza today announced an extension to its partnership with Genmab to cover preclinical and clinical development and manufacturing for a significant portion of Genmab’s pipeline. Lonza’s Ibex Solutions in Visp (CH) is designed to provide Genmab with the flexibility and speed they need to take their candidates towards IND and commercialization.
Tags: SOCMA Member News
Water Science Technologies (WST), a leading blender andchemical solutions provider, announced today that is has been acquired by Chemicals Group (Italmatch), a global specialty chemical group focused on the production and marketing of performance additives for water & process treatment, oil & gas, industrial lubricants and plastics. Grace Matthews, Inc. advised Water Science Technologies on this transaction.
Meridian Adhesives Group ("Meridian") announced the acquisition of Epoxies, Etc. (“Epoxies”), a leading resin formulator of epoxies, urethanes and silicones. Arsenal Capital Partners ("Arsenal") created Meridian in 2018 as its platform in the global adhesives and sealants sector, focusing on high-value adhesives technologies.
Grace Matthews Advises Ritus Corporation And Vanseal Corporation on Sale to Blue Point Capital Partners
Grace Matthews, Inc. and the shareholders of Ritus Corporation, including its subsidiary Classic Molding Company, and Vanseal Corporation (collectively, VRC Holdings Inc., or “VRC”) are pleased to announce the sale of VRC to Blue Point Capital Partners (“Blue Point”). VRC will continue to be led by the current management team, including President Tom Gebhardt. Financial terms of the transaction were not disclosed.
Lonza reported continued positive momentum in its core healthcare businesses in the first six months of 2019. This has driven 6.4% sales and 7.7% CORE EBITDA growth for the group, resulting in a CORE EBITDA margin of 27.8%. Based on H1 2019 results, Lonza confirms the Full-Year 2019 outlook of mid-to-high single-digit sales growth and a sustained CORE EBITDA margin.
Lonza today announced the start of expansion to its bioconjugation facility in Visp, Switzerland together with the successful commercial approval of a third antibody-drug-conjugate (ADC) produced at the site.
FAR Chemical, a leader in scaling up and manufacturing multi-step chemical syntheses and handling highly active materials, announced today that it will expand its Palm Bay, Florida facility. FAR specializes in fine and specialty chemicals such as brominated compounds, organometallics, pyrophoric materials, and the distribution of trimethylchlorosilane.
H.B. Fuller Company (NYSE: FUL) announced today that it has signed an agreement to sell its surfactants, thickeners and dispersants business to Tiarco, LLC (“Tiarco”), a wholly owned subsidiary of Textile Rubber and Chemical Company, Inc., for $71 million.